GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (FRA:TG40) » Definitions » Revenue

Oxurion NV (FRA:TG40) Revenue : €0.08 Mil (TTM As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Oxurion NV Revenue?

Oxurion NV's revenue for the six months ended in Jun. 2024 was €0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €0.08 Mil. Oxurion NV's Revenue per Share for the six months ended in Jun. 2024 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.24.

Warning Sign:

Oxurion NV revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Oxurion NV was -99.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -85.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was -70.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -49.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Oxurion NV's highest 3-Year average Revenue per Share Growth Rate was 139.30% per year. The lowest was -85.50% per year. And the median was -30.40% per year.


Oxurion NV Revenue Historical Data

The historical data trend for Oxurion NV's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Revenue Chart

Oxurion NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.95 2.08 1.13 0.60 0.26

Oxurion NV Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.34 0.18 0.08 -

Competitive Comparison of Oxurion NV's Revenue

For the Biotechnology subindustry, Oxurion NV's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxurion NV's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Revenue distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Revenue falls into.



Oxurion NV Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxurion NV  (FRA:TG40) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Oxurion NV Revenue Related Terms

Thank you for viewing the detailed overview of Oxurion NV's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxurion NV Business Description

Traded in Other Exchanges
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a clinical-stage biopharmaceutical company developing next-generation standard-of-care ophthalmic therapies, which are designed to improve and preserve vision in patients with retinal disorders including Geographic Atrophy (GA). The Group's research and development facilities are located in Belgium. The Company is engaged in the development of drugs to treat blindness diseases.

Oxurion NV Headlines

No Headlines